United Therapeutics (UTHR) Set to Announce Earnings on Wednesday

by · The Markets Daily

United Therapeutics (NASDAQ:UTHR – Get Free Report) will be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $6.16 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same quarter in the prior year, the firm posted $5.24 EPS. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, analysts expect United Therapeutics to post $25 EPS for the current fiscal year and $28 EPS for the next fiscal year.

United Therapeutics Price Performance

UTHR stock opened at $348.65 on Monday. United Therapeutics has a 52 week low of $208.62 and a 52 week high of $377.03. The firm has a market capitalization of $15.46 billion, a P/E ratio of 16.48, a price-to-earnings-growth ratio of 1.27 and a beta of 0.57. The company has a fifty day simple moving average of $354.00 and a two-hundred day simple moving average of $313.31. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,782 shares of the company’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the transaction, the chief financial officer now directly owns 6,426 shares in the company, valued at $2,358,277.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the sale, the chief financial officer now owns 6,426 shares in the company, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $833,350.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 102,812 shares of company stock valued at $35,251,926 in the last 90 days. Company insiders own 12.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on UTHR shares. Wells Fargo & Company increased their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. Bank of America dropped their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. TD Cowen boosted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $361.33.

Get Our Latest Stock Report on United Therapeutics

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also